Biogen News and Research

RSS
Elan rectifies Tysabri Collaboration Agreement breach

Elan rectifies Tysabri Collaboration Agreement breach

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Results further support the benefits of TYSABRI for multiple sclerosis patients

Results further support the benefits of TYSABRI for multiple sclerosis patients

Neurologists recommend oral cladribine for treating multiple sclerosis

Neurologists recommend oral cladribine for treating multiple sclerosis

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

North Carolina Biotechnology Center awarded a transformational grant by the Biogen Idec Foundation

North Carolina Biotechnology Center awarded a transformational grant by the Biogen Idec Foundation

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

Biogen Idec offers to completely acquire Facet

Biogen Idec offers to completely acquire Facet

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

Massachusetts to restore immigrant health care, Colorado Medicaid list grows, Obama in North Carolina

Massachusetts to restore immigrant health care, Colorado Medicaid list grows, Obama in North Carolina

Costly biologics drugs prompt exclusivity debate

Costly biologics drugs prompt exclusivity debate

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Rituximab linked to viral brain infection

Rituximab linked to viral brain infection

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Stromedix awarded U.S. patent for antibody-based therapeutics

Stromedix awarded U.S. patent for antibody-based therapeutics

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

FDA accepts Zevalin supplemental biologics license application

FDA accepts Zevalin supplemental biologics license application